Sirolimus Versus Anti-Vascular Endothelial Growth Factor (antiVEGF) for Wet AMD
Status:
Completed
Trial end date:
2017-01-01
Target enrollment:
Participant gender:
Summary
Phase 2 clinical trial, single site, randomized, subject-masked study to determine safety and
efficacy of intravitreal injections of Sirolimus in subjects with wet Age-Related Macular
Degeneration (wet AMD) with persistent intraretinal or subretinal edema due to neovascular
AMD despite previous AntiVEGF treatment.